Citius Oncology (NASDAQ:CTOR – Get Free Report) posted its earnings results on Friday. The company reported ($0.09) EPS for the quarter, Zacks reports.
Citius Oncology Stock Performance
Shares of NASDAQ CTOR opened at $1.25 on Friday. The company has a quick ratio of 0.08, a current ratio of 0.34 and a debt-to-equity ratio of 0.08. Citius Oncology has a fifty-two week low of $0.85 and a fifty-two week high of $49.00. The company’s 50 day simple moving average is $1.18.
Analyst Ratings Changes
Separately, Maxim Group initiated coverage on shares of Citius Oncology in a research report on Wednesday, November 27th. They issued a “buy” rating and a $3.00 price objective for the company.
About Citius Oncology
Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.
Read More
- Five stocks we like better than Citius Oncology
- What is a Death Cross in Stocks?
- 3 Dividend ETFs to Capitalize on the Slide in Chip Stocks
- How to Invest in the Best Canadian Stocks
- Is Chevron Stock Primed for Growth After Profit-Boosting News?
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- MarketBeat Week in Review – 02/10 – 02/14
Receive News & Ratings for Citius Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
